0.00
100.00%
-0.86
Acelrx Pharmaceuticals Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.8386 pivot point. If it approaches the $0.7007 support level, significant changes may occur.
Previous Close:
$0.86
Open:
$0
24h Volume:
0
Market Cap:
$14.58M
Revenue:
$2.82M
Net Income/Loss:
$-21.36M
P/E Ratio:
0.00
EPS:
-3.09
Net Cash Flow:
$-19.10M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Acelrx Pharmaceuticals Inc Stock (ACRX) Company Profile
Name
Acelrx Pharmaceuticals Inc
Sector
Phone
650 216 3500
Address
25821 Industrial Boulevard, Suite 400, Hayward, CA
Acelrx Pharmaceuticals Inc Stock (ACRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-20-20 | Downgrade | Credit Suisse | Neutral → Underperform |
Nov-11-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Aug-05-19 | Resumed | Credit Suisse | Outperform |
Jul-10-19 | Resumed | Credit Suisse | Outperform |
Apr-24-19 | Resumed | B. Riley FBR | Buy |
Feb-15-19 | Initiated | Credit Suisse | Outperform |
Oct-23-18 | Initiated | B. Riley FBR | Buy |
Oct-13-17 | Downgrade | Jefferies | Buy → Hold |
Oct-13-17 | Reiterated | RBC Capital Mkts | Outperform |
Jul-14-17 | Resumed | Jefferies | Buy |
Sep-15-16 | Reiterated | ROTH Capital | Buy |
Aug-05-16 | Downgrade | Stifel | Buy → Hold |
Oct-30-15 | Upgrade | Jefferies | Hold → Buy |
Oct-05-15 | Reiterated | ROTH Capital | Buy |
Sep-02-15 | Initiated | H.C. Wainwright | Buy |
Jul-10-15 | Resumed | ROTH Capital | Buy |
May-06-15 | Reiterated | Mizuho | Neutral |
May-05-15 | Reiterated | RBC Capital Mkts | Outperform |
Mar-10-15 | Reiterated | RBC Capital Mkts | Outperform |
Mar-09-15 | Downgrade | Mizuho | Buy → Neutral |
View All
Acelrx Pharmaceuticals Inc Stock (ACRX) Latest News
Acelrx Pharmaceuticals Inc Stock (ACRX) Financials Data
Acelrx Pharmaceuticals Inc (ACRX) Revenue 2024
ACRX reported a revenue (TTM) of $2.82 million for the quarter ending December 31, 2021, a -47.97% decline year-over-year.
Acelrx Pharmaceuticals Inc (ACRX) Net Income 2024
ACRX net income (TTM) was -$21.36 million for the quarter ending September 30, 2023, a -145.15% decrease year-over-year.
Acelrx Pharmaceuticals Inc (ACRX) Cash Flow 2024
ACRX recorded a free cash flow (TTM) of -$19.10 million for the quarter ending September 30, 2023, a +38.90% increase year-over-year.
Acelrx Pharmaceuticals Inc (ACRX) Earnings per Share 2024
ACRX earnings per share (TTM) was -$2.23 for the quarter ending September 30, 2023, a -142.48% decline year-over-year.
About Acelrx Pharmaceuticals Inc
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Cap:
|
Volume (24h):